Feb 20, 2024 | News
Calgary, Alberta, February 20, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse...
Jan 19, 2024 | News
Calgary, Alberta, Canada, January 19, 2024 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private...
Jan 8, 2024 | News
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study...
Nov 16, 2023 | News
Calgary, Alberta (November 16, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome...
Aug 22, 2023 | News
Calgary, Alberta (August 22, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its 4-week good...
Jul 11, 2023 | News
Calgary, Alberta – (July 10, 2023) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has been selected to present the Company’s scientific...
